3-[4-fluoro-2-(trifluoromethyl)phenyl]prop-2-enoic Acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 3-[4-fluoro-2-(trifluoromethyl)phenyl]prop-2-enoic Acid
• 化学式: C₁₀H₆F₄O₂
• 分子量: 234.15
• InChiKey: OREHSCSLACWBTF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-[4-fluoro-2-(trifluoromethyl)phenyl]prop-2-enoic Acid 在 叠氮磷酸二苯酯 、 三溴化磷 作用下， 以 二苯基甲烷 、 甲苯 为溶剂， 反应 12.0h， 生成 1-Bromo-7-fluoro-5-(trifluoromethyl)isoquinoline
  参考文献：
  名称：

  Nitrogen-Containing Heterocyclic Compound, Pharmaceutical Compositions thereof and Use thereof

  摘要：

  Disclosed is a nitrogen-containing heterocyclic compound, pharmaceutical compositions thereof and use thereof. The present disclosure provides a nitrogen-containing heterocyclic compound represented by formula I, a pharmaceutically acceptable salt thereof, a solvate thereof, a solvate of pharmaceutically acceptable salt thereof, a crystal thereof, a stereoisomer thereof, a tautomer thereof or an isotopically labeled compound thereof. The nitrogen-containing heterocyclic compound represented by formula I is expected to treat and/or prevent various PI3K-meditated diseases.

  公开号：

  US20240158408A1
• 作为产物：
  描述：

  丙二酸 、 4-氟-2-(三氟甲基)苯甲醛 在 哌啶 、 吡啶 作用下， 以53 %的产率得到3-[4-fluoro-2-(trifluoromethyl)phenyl]prop-2-enoic Acid
  参考文献：
  名称：

  Nitrogen-Containing Heterocyclic Compound, Pharmaceutical Compositions thereof and Use thereof

  摘要：

  Disclosed is a nitrogen-containing heterocyclic compound, pharmaceutical compositions thereof and use thereof. The present disclosure provides a nitrogen-containing heterocyclic compound represented by formula I, a pharmaceutically acceptable salt thereof, a solvate thereof, a solvate of pharmaceutically acceptable salt thereof, a crystal thereof, a stereoisomer thereof, a tautomer thereof or an isotopically labeled compound thereof. The nitrogen-containing heterocyclic compound represented by formula I is expected to treat and/or prevent various PI3K-meditated diseases.

  公开号：

  US20240158408A1

文献信息

• Aniline derivatives, their manufacture and use as pharmaceutical agents
  申请人：——

  公开号：US20040254217A1

  公开（公告）日：2004-12-16

  Compounds of formula (I) 1 are useful in the therapy and/or prevention of illnesses with known over-expression of receptor tyrosine kinases of the HER-family like HER-2 and EGFR (HER-1). Accordingly, these compounds are useful for the treatment of diseases such as cancer in humans or animals.

  式(I)1的化合物在治疗和/或预防已知过度表达HER家族受体酪氨酸激酶的疾病（如HER-2和EGFR（HER-1））方面是有用的。因此，这些化合物对于治疗人类或动物的癌症等疾病是有用的。
• Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase Type 1
  申请人：Claremon David A.

  公开号：US20110136821A1

  公开（公告）日：2011-06-09

  This invention relates to novel compounds of the Formulae I or II and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD 1 in mammals. Formula (I).

  本发明涉及公式I或II的新化合物及其药学上可接受的盐，以及其制备的药物组合物，用于治疗与哺乳动物中11β-HSD 1的调节或抑制相关的疾病。公式（I）。
• Inhibitors of 11β-hydroxysteroid dehydrogenase type 1
  申请人：Claremon David A.

  公开号：US08383629B2

  公开（公告）日：2013-02-26

  This invention relates to novel compounds of the Formulae I or II and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD 1 in mammals. Formula (I).

  该发明涉及公式I或II的新化合物及其药学上可接受的盐，以及这些化合物的药物组合物，可用于治疗与哺乳动物中11β-HSD 1的调节或抑制有关的疾病。公式（I）。
• Nitrogen-Containing Heterocyclic Compound, Pharmaceutical Compositions thereof and Use thereof
  申请人：280 Bio, Inc.

  公开号：US20240158408A1

  公开（公告）日：2024-05-16

  Disclosed is a nitrogen-containing heterocyclic compound, pharmaceutical compositions thereof and use thereof. The present disclosure provides a nitrogen-containing heterocyclic compound represented by formula I, a pharmaceutically acceptable salt thereof, a solvate thereof, a solvate of pharmaceutically acceptable salt thereof, a crystal thereof, a stereoisomer thereof, a tautomer thereof or an isotopically labeled compound thereof. The nitrogen-containing heterocyclic compound represented by formula I is expected to treat and/or prevent various PI3K-meditated diseases.